MNLO stock forecast
Our latest prediction for Menlo Therapeutics, Inc.'s stock price was made on the Jan. 25, 2018 when the stock price was at 28.71$.
In the short term (2weeks), MNLO's stock price should outperform the market by 3.49%. During that period the price should oscillate between -2.76% and +3.48%.
In the medium term (3months), MNLO's stock price should outperform the market by 7.89%. During that period the price should oscillate between -4.83% and +10.02%.Get email alerts
About Menlo Therapeutics, Inc.
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
At the moment the company generates 13M USD in revenues.
On its last earning announcement, the company reported a loss of -1.86$ per share.
The book value per share is 6.88$
Three months stock forecastJan. 25, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|